AR069746A1 - Conjugados de anticuerpos anti- rg-1 - Google Patents

Conjugados de anticuerpos anti- rg-1

Info

Publication number
AR069746A1
AR069746A1 ARP080105135A ARP080105135A AR069746A1 AR 069746 A1 AR069746 A1 AR 069746A1 AR P080105135 A ARP080105135 A AR P080105135A AR P080105135 A ARP080105135 A AR P080105135A AR 069746 A1 AR069746 A1 AR 069746A1
Authority
AR
Argentina
Prior art keywords
antibody
human
conjugate
associated molecule
binds
Prior art date
Application number
ARP080105135A
Other languages
English (en)
Original Assignee
Medarex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40427118&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR069746(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Medarex Inc filed Critical Medarex Inc
Publication of AR069746A1 publication Critical patent/AR069746A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6869—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from a cell of the reproductive system: ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
    • A61K47/6809—Antibiotics, e.g. antitumor antibiotics anthracyclins, adriamycin, doxorubicin or daunomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Reproductive Health (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)

Abstract

Anticuerpos anti-RG-1, (homologo de la familia de la MINDIN /F-espondina) fragmentos de anticuerpos, o miméticos de los anticuerpos conjugados con moléculas asociadas, tales como fármacos, radioisotopos y citotoxinas, donde la molécula asociada ejerce su efecto sin importar si el conjugado enlazado a RG-1 es interiorizado dentro de una célula diana, son utiles para tratar cánceres. Reivindicacion 1: Un conjugado de anticuerpo-molécula asociada que comprende un anticuerpo monoclonal humano o una porcion de enlace al antígeno del mismo conjugado con una molécula asociada, donde el anticuerpo o la porcion de enlace al antígeno del mismo se enlaza a RG-1 humano y el conjugado exhibe al menos una de las siguientes características: (a) se enlaza a RG-1 humano con una KD de 1 x 10-8 M o menor; (b) inhibe el crecimiento de las células que expresan RG-1 in vivo
ARP080105135A 2007-11-30 2008-11-26 Conjugados de anticuerpos anti- rg-1 AR069746A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US99169007P 2007-11-30 2007-11-30

Publications (1)

Publication Number Publication Date
AR069746A1 true AR069746A1 (es) 2010-02-17

Family

ID=40427118

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP080105135A AR069746A1 (es) 2007-11-30 2008-11-26 Conjugados de anticuerpos anti- rg-1

Country Status (18)

Country Link
US (1) US20110020329A1 (es)
EP (1) EP2211908A2 (es)
JP (1) JP2011505371A (es)
KR (1) KR20100101122A (es)
CN (1) CN101951960A (es)
AR (1) AR069746A1 (es)
AU (1) AU2008331507A1 (es)
BR (1) BRPI0819765A2 (es)
CA (1) CA2707443A1 (es)
CL (1) CL2008003525A1 (es)
CO (1) CO6210734A2 (es)
EA (1) EA201000921A1 (es)
IL (1) IL206060A0 (es)
MX (1) MX2010005683A (es)
NZ (1) NZ586514A (es)
TW (1) TW200930407A (es)
WO (1) WO2009073524A2 (es)
ZA (1) ZA201003729B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2007000387A (es) * 2004-07-16 2007-03-28 Micromet Ag Polipeptidos de expresion mejorada.
DK2344478T3 (da) 2008-11-03 2017-11-27 Syntarga Bv Cc-1065 analoger og deres konjugater
RU2730502C2 (ru) 2010-04-21 2020-08-24 Синтарга Б.В. Новые конъюгаты аналогов сс-1065 и бифункциональные линкеры
NZ604007A (en) * 2010-05-27 2015-03-27 Genmab As Monoclonal antibodies against her2 epitope
WO2011147986A1 (en) 2010-05-27 2011-12-01 Genmab A/S Monoclonal antibodies against her2
US8852599B2 (en) * 2011-05-26 2014-10-07 Bristol-Myers Squibb Company Immunoconjugates, compositions for making them, and methods of making and use
PT3092010T (pt) 2014-01-10 2018-09-28 Synthon Biopharmaceuticals Bv Método para purificação de conjugados anticorpo-fármaco ligados por cys
CN105636591B (zh) * 2014-01-29 2020-04-07 上海恒瑞医药有限公司 配体-细胞毒性药物偶联物、其制备方法及其应用
PE20200617A1 (es) 2017-07-31 2020-03-11 Tizona Therapeutics Anticuerpos anti-cd39, composiciones que comprenden anticuerpos anti-cd39, y metodos de uso de anticuerpos anti-cd39

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4978757A (en) * 1984-02-21 1990-12-18 The Upjohn Company 1,2,8,8a-tetrahydrocyclopropa (C) pyrrolo [3,2-e)]-indol-4(5H)-ones and related compounds
US4912227A (en) * 1984-02-21 1990-03-27 The Upjohn Company 1,2,8,8A-tetrahydrocyclopropa(c)pyrrolo(3,2-e)-indol-4-(5H)-ones and related compounds
US5332837A (en) * 1986-12-19 1994-07-26 The Upjohn Company CC-1065 analogs
US5084468A (en) * 1988-08-11 1992-01-28 Kyowa Hakko Kogyo Co., Ltd. Dc-88a derivatives
JP2598116B2 (ja) * 1988-12-28 1997-04-09 協和醗酵工業株式会社 新規物質ｄｃ１１３
US5187186A (en) * 1989-07-03 1993-02-16 Kyowa Hakko Kogyo Co., Ltd. Pyrroloindole derivatives
JP2510335B2 (ja) * 1989-07-03 1996-06-26 協和醗酵工業株式会社 Ｄｃ―８８ａ誘導体
KR100208957B1 (ko) * 1990-04-25 1999-07-15 로렌스 티. 마이젠헬더 신규한 cc-1065 유사체
US6214345B1 (en) * 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates
KR100350260B1 (ko) * 1994-04-22 2003-01-06 교와 핫꼬 고교 가부시끼가이샤 피롤로인돌유도체
JPH07309761A (ja) * 1994-05-20 1995-11-28 Kyowa Hakko Kogyo Co Ltd デュオカルマイシン誘導体の安定化法
US5871969A (en) * 1996-02-12 1999-02-16 Human Genome Sciences, Inc. Nucleic acids encoding human neuronal attachment factor-1
US6682902B2 (en) * 1999-12-16 2004-01-27 Schering Aktiengesellschaft DNA encoding a novel RG1 polypeptide
CN101671335A (zh) * 2001-05-31 2010-03-17 梅达莱克斯公司 细胞毒素、其有用的前体药物、连接基团和稳定剂
CA2459308A1 (en) * 2001-09-07 2003-03-20 Dale L. Boger Cbi analogues of cc-1065 and the duocarmycins
US7091186B2 (en) * 2001-09-24 2006-08-15 Seattle Genetics, Inc. p-Amidobenzylethers in drug delivery agents
MXPA06000798A (es) * 2003-07-22 2006-04-07 Schering Ag Anticuerpos de rg1 y usos de los mismos.
WO2005112919A2 (en) * 2004-05-19 2005-12-01 Medarex, Inc. Self-immolative linkers and drug conjugates
US7691962B2 (en) * 2004-05-19 2010-04-06 Medarex, Inc. Chemical linkers and conjugates thereof
US7714016B2 (en) * 2005-04-08 2010-05-11 Medarex, Inc. Cytotoxic compounds and conjugates with cleavable substrates
ES2416136T3 (es) * 2005-09-26 2013-07-30 Medarex, Inc. Conjugados de anticuerpo-fármaco y su uso
CA2627190A1 (en) * 2005-11-10 2007-05-24 Medarex, Inc. Duocarmycin derivatives as novel cytotoxic compounds and conjugates
JP5189082B2 (ja) * 2006-05-25 2013-04-24 バイエル・ファルマ・アクチェンゲゼルシャフト 二量体分子複合体

Also Published As

Publication number Publication date
CO6210734A2 (es) 2010-10-20
ZA201003729B (en) 2011-08-31
MX2010005683A (es) 2010-06-11
KR20100101122A (ko) 2010-09-16
NZ586514A (en) 2012-05-25
WO2009073524A2 (en) 2009-06-11
WO2009073524A3 (en) 2009-12-10
CL2008003525A1 (es) 2010-01-22
US20110020329A1 (en) 2011-01-27
EA201000921A1 (ru) 2010-12-30
IL206060A0 (en) 2010-11-30
CA2707443A1 (en) 2009-06-11
BRPI0819765A2 (pt) 2015-05-05
TW200930407A (en) 2009-07-16
AU2008331507A1 (en) 2009-06-11
JP2011505371A (ja) 2011-02-24
CN101951960A (zh) 2011-01-19
EP2211908A2 (en) 2010-08-04

Similar Documents

Publication Publication Date Title
AR069746A1 (es) Conjugados de anticuerpos anti- rg-1
AR069747A1 (es) Conjugado anticuerpo monoclonal anti-b7h4- farmaco y metodos de utilizacion
AR064109A1 (es) Anticuerpos humanos que se enlazan al cd22 y sus usos
CY1123030T1 (el) Υλικο και μεθοδοι για θεραπεια ή αποτροπη σχετικων me her-3 ασθενειων
EA201990781A9 (ru) Анти-steap2 антитела, конъюгаты антитело-лекарственное средство и биспецифические антигенсвязывающие молекулы, которые связывают steap2 и cd3, и их применение
AR064360A1 (es) Anticuerpos humanos que se enlazan a cd70 y usos de los mismos
CY1121536T1 (el) Ανθρωπινα αντισωματα εναντι-αλφα-συνουκλεϊνης
EA201270654A1 (ru) Моноклональные антитела, связывающие b7h6, и их применение
CY1119591T1 (el) Πρωτεϊνες ειδικης συνδεσης και χρησεις αυτων
AR050642A1 (es) Anticuerpos anti-5t4 humanizados y conjugados anticuerpo anti-5t4/ calicheamicina
EP2570137A3 (en) Antibodies that bind human dendritic and epithelial cell 205 (DEC-205)
NI201000021A (es) Anticuerpos humanos de alta afinidad de factor de crecimiento de nervio humano.
AR069903A1 (es) Conjugado anticuerpo- molecula asociada dirigidos a la proteina tirosina quinasa 7 (ptk 7), composicion farmaceutica que lo comprende, acido nucleico, factor de expresion y celula huesped relacionados y su uso para preparar un medicamento util para el tratamiento o prevencion de cancer
AR069290A1 (es) Anticuerpos monoclonales que se unen al hgm -csf (factor estimulante de la colonia de granulocitos-macrofagos) y las composiciones medicas que los comprenden
BR112012024564A2 (pt) anticorpos contra csf-1r
CY1114953T1 (el) Αντι-βητα-αμυλοειδους αντισωμα και χρησεις αυτου
WO2008091911A8 (en) Use of antibody conjugates
MY150246A (en) Alpha 5 - beta 1 antibodies and their uses
MX2020011554A (es) Composiciones y metodos relacionados con conjugados de farmacos de anticuerpo anti grupo de diferenciacion 19 (cd19).
AR073538A1 (es) Anticuerpos multiespecificos que se unen especificamente al receptor del factor de crecimiento epidermico humano 2 (her2) y al factor de crecimiento endotelial vascular (vegf)
AR078751A1 (es) Moleculas de anticuerpo anti-gcc (guanililo ciclasa c) y composiciones y metodos relacionados
BR112012014984A2 (pt) anticorpos dirigidos contra o receptor da transferrina e as suas utilizacoes para a imunoterapia dos tumores que dependem do ferro
PE20091713A1 (es) Inhibicion del receptor para la proteina estimulante del macrofago (ron), composiciones y metodos
MX2009009926A (es) Anticuerpo tumor-especifico humano monoclonal.
ES2639026T3 (es) Anticuerpos totalmente humanos específicos para CADM1

Legal Events

Date Code Title Description
FA Abandonment or withdrawal